MapLight Therapeutics (MPLT) Q3 2025 earnings summary

Executive summary

• Clinical-stage biopharmaceutical company advancing multiple Phase 2 trials for CNS disorders, including schizophrenia, Alzheimer's disease psychosis, and autism spectrum disorder, with topline results expected in 2026 and 2027.

• Completed enrollment in the IRIS Phase 2 study for ML-004 in autism spectrum disorder; topline results expected in H2 2026.

• Net loss for the nine months ended September 30, 2025 was $81.6 million, up from $56.4 million in the prior year period; accumulated deficit reached $281.0 million.

• Closed IPO and concurrent private placement in October 2025, raising $296.5 million gross and $269.8 million net proceeds, with all outstanding preferred stock converting to common stock.

Financial highlights

• Research and development expenses rose to $73.7 million for the nine months ended September 30, 2025, with Q3 2025 R&D expenses at $27.1 million, mainly due to increased clinical trial and employee-related costs.

• General and administrative expenses were $12.0 million for the nine months ended September 30, 2025, with Q3 2025 G&A expenses at $4.4 million, slightly up year-over-year.

• Cash, cash equivalents, and short-term investments totaled $227.2 million as of September 30, 2025.

• Net cash used in operating activities was $91.3 million for the nine months ended September 30, 2025.

• Net loss for Q3 2025 was $29.4 million, compared to $19.0 million in Q3 2024.

Outlook and guidance

• Cash position, including IPO and private placement proceeds, expected to fund operations through 2027.

• Topline results from Phase 2 ZEPHYR trial for schizophrenia anticipated in H2 2026; VISTA trial for Alzheimer's disease psychosis in H2 2027.

• IRIS Phase 2 study results for autism spectrum disorder expected in H2 2026.

• IND-enabling studies for ML-021 in Parkinson's disease expected to complete in H2 2026.

• Company anticipates continued significant operating losses as it advances clinical and preclinical programs.